Taking these results together, we suggest that the enhanced antitumor immunity and tumor growth inhibition seen in IL-33-treated TB mice are due to a newly developed immunogenic population of CD103+ cDC1s in the spleen. The gene discussed is IL33; the disease is neoplasm.